Van Berkom & Associates Inc. Has $83.37 Million Stock Position in Privia Health Group, Inc. $PRVA

Van Berkom & Associates Inc. raised its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 5.4% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 4,053,043 shares of the company’s stock after buying an additional 208,787 shares during the period. Privia Health Group makes up about 2.8% of Van Berkom & Associates Inc.’s investment portfolio, making the stock its 8th biggest position. Van Berkom & Associates Inc.’s holdings in Privia Health Group were worth $83,371,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Renaissance Group LLC bought a new position in Privia Health Group in the fourth quarter worth approximately $7,776,000. Principal Financial Group Inc. raised its position in Privia Health Group by 1.6% during the 4th quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock valued at $66,099,000 after purchasing an additional 43,589 shares in the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of Privia Health Group in the 1st quarter worth $1,055,000. JPMorgan Chase & Co. lifted its holdings in shares of Privia Health Group by 26.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 148,709 shares of the company’s stock worth $3,703,000 after buying an additional 30,845 shares during the period. Finally, Horizon Investments LLC purchased a new stake in shares of Privia Health Group in the 4th quarter worth $603,000. 94.48% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PRVA has been the topic of several research reports. Evercore set a $26.00 price target on Privia Health Group in a research note on Wednesday, April 8th. Barclays lowered their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Canaccord Genuity Group cut their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Zacks Research lowered shares of Privia Health Group from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Privia Health Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.15.

Insider Transactions at Privia Health Group

In related news, CEO Parth Mehrotra sold 105,439 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $22.55, for a total transaction of $2,377,649.45. Following the sale, the chief executive officer owned 450,004 shares of the company’s stock, valued at $10,147,590.20. This trade represents a 18.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $25.33, for a total value of $2,231,826.30. Following the completion of the transaction, the director owned 76,651 shares in the company, valued at $1,941,569.83. This trade represents a 53.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 478,855 shares of company stock valued at $12,099,109. Corporate insiders own 5.70% of the company’s stock.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $26.90 on Monday. The stock has a market capitalization of $3.39 billion, a PE ratio of 168.14, a price-to-earnings-growth ratio of 2.13 and a beta of 0.83. The stock’s fifty day simple moving average is $24.12 and its two-hundred day simple moving average is $23.26. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $28.82.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.